HK1203616A1 - Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbv - Google Patents

Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbv

Info

Publication number
HK1203616A1
HK1203616A1 HK15104040.5A HK15104040A HK1203616A1 HK 1203616 A1 HK1203616 A1 HK 1203616A1 HK 15104040 A HK15104040 A HK 15104040A HK 1203616 A1 HK1203616 A1 HK 1203616A1
Authority
HK
Hong Kong
Prior art keywords
hbv
immunocomplexes
patients
chronic
response prediction
Prior art date
Application number
HK15104040.5A
Other languages
English (en)
Chinese (zh)
Inventor
Ursula Klause
Berthold Hipp
Veit Peter Grunert
Barbara Upmeier
Uri Lopatin
Niet Annikki De
Henk Reesink
Hans Zaaijer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1203616A1 publication Critical patent/HK1203616A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15104040.5A 2012-02-20 2015-04-27 Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbv HK1203616A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12156192.2A EP2629096A1 (fr) 2012-02-20 2012-02-20 Immuno-complexes de l'HBV pour la prédiction de la réponse et le suivi du traitement de patients souffrant de l'hépatite B chronique
PCT/EP2013/053150 WO2013124229A1 (fr) 2012-02-20 2013-02-18 Immunocomplexes vhb utilisés pour prévoir la réponse des patients atteints d'hépatite b chronique à un traitement et surveiller ce traitement

Publications (1)

Publication Number Publication Date
HK1203616A1 true HK1203616A1 (en) 2015-10-30

Family

ID=47757571

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104040.5A HK1203616A1 (en) 2012-02-20 2015-04-27 Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbv

Country Status (7)

Country Link
US (1) US20150192583A1 (fr)
EP (2) EP2629096A1 (fr)
JP (1) JP2015508892A (fr)
CN (1) CN104126124A (fr)
CA (1) CA2863106A1 (fr)
HK (1) HK1203616A1 (fr)
WO (1) WO2013124229A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6738319B2 (ja) * 2015-03-30 2020-08-12 雅史 溝上 インターフェロン治療効果予測方法及びそれを用いたｂ型肝炎患者の治療用医薬組成物
EP3322820A1 (fr) * 2015-07-15 2018-05-23 H. Hoffnabb-La Roche Ag Biomarqueurs pour la réponse au traitement du hbv
US20190339275A1 (en) * 2016-11-11 2019-11-07 Melbourne Health Assay for determining hepatitis b clearance
WO2019123398A1 (fr) * 2017-12-21 2019-06-27 New Zealand Health Innovation Hub Management Limited Procédé d'analyse de mutations dans le virus de l'hépatite b et utilisations de celui-ci
US20210239700A1 (en) * 2018-05-04 2021-08-05 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
CN110564894B (zh) * 2019-09-10 2023-04-07 深圳市罗湖区人民医院 干扰物对荧光定量pcr检测hbv dna的干扰评价方法
CN111474187A (zh) * 2020-04-09 2020-07-31 三峡大学 一种免疫电镜免疫反应盒
CN115466802B (zh) * 2022-10-28 2023-12-12 北京大学 Tp53bp2在调控干扰素信号通路及抗病毒中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726011A (en) * 1994-03-31 1998-03-10 Virginia Commonwealth University Method for diagnosing chronic hepatitis B virus infection
CN1365286A (zh) * 1999-06-22 2002-08-21 希龙公司 治疗慢性乙型肝炎病毒感染的方法
CN1261455C (zh) * 2002-07-19 2006-06-28 余宙耀 一种重组人源性抗乙肝表面抗原（HBsAg）Fab抗体及其制取方法
DE10339927A1 (de) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
GB0326416D0 (en) * 2003-11-12 2003-12-17 Karolinska Innovations Ab Methods and means relating to hepatitis B infection
US20090170926A1 (en) * 2004-03-31 2009-07-02 Monash Univeristy Antiviral agents
CA2686427C (fr) 2007-05-08 2013-07-16 F. Hoffmann-La Roche Ag Procede de detection d'anticorps specifiques de la classe des immunoglobulines g
EP2419727A1 (fr) * 2009-04-14 2012-02-22 Schering Corporation Biomarqueurs de sensibilité aux interférons alpha

Also Published As

Publication number Publication date
EP2629096A1 (fr) 2013-08-21
JP2015508892A (ja) 2015-03-23
CN104126124A (zh) 2014-10-29
CA2863106A1 (fr) 2013-08-29
EP2817631A1 (fr) 2014-12-31
US20150192583A1 (en) 2015-07-09
WO2013124229A1 (fr) 2013-08-29

Similar Documents

Publication Publication Date Title
HRP20180939T1 (hr) Kombinirana terapija za liječenje multiple skleroze
HK1203616A1 (en) Hbv immunocomplexes for response prediction and therapy monitoring of chronic hbv patients hbv hbv
ZA201604110B (en) New treatment of chronic ulcers
SG11201501075RA (en) Medical devices for blood reflux prevention and methods of use
IL239084A0 (en) Devices to support medical care
ZA201502503B (en) Hppd variants and methods of use
EP2811897A4 (fr) Kiosque médical et son procédé d'utilisation
IL263661A (en) Combination therapy for the treatment of glioblastoma
ZA201405248B (en) Anesthetic compounds and related methods of use
HK1206937A1 (en) Methods of administering pirfenidone therapy
EP2906208A4 (fr) Traitement thérapeutique
AU339607S (en) Medical device for treatment of sleep disorders
HK1200348A1 (en) Methods and materials for treatment of pompes disease
EP2867239A4 (fr) Oxabicycloheptanes et oxabicycloheptènes pour le traitement du diabète
HK1210008A1 (en) Systems and methods for treatment of sleep apnea
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
PT3228313T (pt) Formas de dosagem e utilizações terapêuticas de l-4-cloroquinurenina
IL245604A0 (en) Combination treatment of anti-mif antibodies and chemotherapeutic agents
GB201201778D0 (en) Treatment of inflammatory respiratory disease
EP2854878A4 (fr) Dispositif médical pour le traitement de plaies